How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,484 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. TCM non-pharmacological interventions for antibiotic-associated diarrhea (AAD): a systematic review and network meta-analysis

TCM non-pharmacological interventions for antibiotic-associated diarrhea (AAD): a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any (...) . Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital

2020 PROSPERO

182. The effectiveness of solar disinfection water treatment method for reducing childhood diarrhea: A systematic review and meta-analysis protocol

The effectiveness of solar disinfection water treatment method for reducing childhood diarrhea: A systematic review and meta-analysis protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) , editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from

2020 PROSPERO

183. A systematic review of the efficacy and safety of moxibustion with salt for Diarrhea-Predominant irritable bowel syndrome

A systematic review of the efficacy and safety of moxibustion with salt for Diarrhea-Predominant irritable bowel syndrome Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any (...) . Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital

2020 PROSPERO

184. Comparative efficacy and safety of different oral rehydration solutions for Children with severe acute malnutrition and diarrhea: systematic review and network meta-analysis of randomized trials

Comparative efficacy and safety of different oral rehydration solutions for Children with severe acute malnutrition and diarrhea: systematic review and network meta-analysis of randomized trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears (...) . Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures

2020 PROSPERO

185. Umbilical Moxibustion for Diarrhea-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

Umbilical Moxibustion for Diarrhea-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) . No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data

2020 PROSPERO

186. A meta-analysis on infantile massage for diarrhea.

A meta-analysis on infantile massage for diarrhea. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith (...) . Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data are not reported or unclear, we will attempt to contact

2020 PROSPERO

187. A meta-analysis of the effects of Mulstrain-probiotics in children with acute diarrhea

A meta-analysis of the effects of Mulstrain-probiotics in children with acute diarrhea Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites (...) tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data are not reported

2020 PROSPERO

188. Effectiveness of warm needle moxibustion for diarrhea-predominant irritable bowel syndrome (IBS-D): systematic review and meta-analysis

Effectiveness of warm needle moxibustion for diarrhea-predominant irritable bowel syndrome (IBS-D): systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration (...) . Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital

2020 PROSPERO

189. Effectiveness of probiotics in eliminating duration of acute infectious diarrhea in children: a systematic review and meta-analysis of randomized controlled trials

Effectiveness of probiotics in eliminating duration of acute infectious diarrhea in children: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability (...) (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we

2020 PROSPERO

190. Cost Effectiveness of Interventions for Diarrhoea Management among Children in Community-based Settings in LMICs: A Systematic Review

Cost Effectiveness of Interventions for Diarrhoea Management among Children in Community-based Settings in LMICs: A Systematic Review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record (...) . Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital

2020 PROSPERO

191. Efficacy of Faecal Microbiota Transplant against Clostridium difficile diarrhoea: systematic review and meta-analysis

Efficacy of Faecal Microbiota Transplant against Clostridium difficile diarrhoea: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated (...) study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler

2020 PROSPERO

192. Efficacy of Shenlingbaizhu Powder for Antibiotic-associated Diarrhea: A Systematic Review And A Meta-analysis

Efficacy of Shenlingbaizhu Powder for Antibiotic-associated Diarrhea: A Systematic Review And A Meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) . No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data

2020 PROSPERO

193. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline

, should be accompanied by cognitive-behavioral therapies whenever possible. Short/intermediate acting benzodiazepine receptor agonists (benzodiazepines [BZDs] or newer BZD receptor agonistic modulators [BzRAs]) or ramelteon were recommended as first-line pharmacotherapy. Other drugs, such as sedating antidepressants or anticonvulsant medications were recommended as second- or third-line agents, particularly when comorbidities (e.g. mood disorder or epilepsy) are present. Other, non-prescription drugs (...) impairment), and work-related accidents. General treatment measures for insomnia include the treatment of comorbid medical and psychiatric conditions, modifying sleep-interfering medications and substances, and optimizing the sleep environment. Specific treatments for insomnia fall into two primary categories. Non-pharmacological therapies, largely cognitive behavioral in nature, have been the subject of numerous meta-analyses and practice guidelines. , – Pharmacological therapy, including over

2017 American Academy of Sleep Medicine

194. Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies.

: Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies. Study Start Date : December 2014 Actual Primary Completion Date : December 2015 Actual Study Completion Date : December 2015 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment (...) . Outcome Measures Go to Primary Outcome Measures : Efficacy measured by the decrease in the intensity of diarrhea and / or anti-diarrheal consumption [ Time Frame: 1 month ] Effectiveness of acetylsalicylic acid versus diosmectite Secondary Outcome Measures : Toxicity [ Time Frame: Three months ] Diarrhea decrease 3 months after the introduction of acetylsalicylic acid or diosmectite; Proportion of patients with a decrease in the grade of diarrhea during the months following the introduction

2014 Clinical Trials

195. MI - secondary prevention

. May 2009 — minor update to include drug safety advice from the Medicines and Healthcare products Regulatory Agency on the use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor antagonists in women who are breastfeeding. Issued in June 2009. April 2009 — updated to include the Quality Outcomes Framework (QOF) indicators for coronary heart disease from the General Medical Services (GMS) contract in the Goals and outcome measures section. Issued in May 2009. October 2008 — minor (...) on , , and . Ask/reassure the person about any they may have relating to returning to work, resuming normal activities etc. Continue prescribing medications that were initiated in secondary care as part of any agreed shared care arrangement: People who have had an acute MI should generally have been offered treatment with an ACE (angiotensin-converting enzyme) inhibitor, dual antiplatelet therapy (aspirin plus a second antiplatelet agent [clopidogrel or ticagrelor]), a beta-blocker, and a statin

2019 NICE Clinical Knowledge Summaries

196. A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study. (Abstract)

A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study. The aim of this single-arm phase II clinical trial was to evaluate whether the alternate-day administration of S-1 plus irinotecan would reduce the incidence of severe diarrhea in comparison to consecutive-day S-1 administration (standard IRIS regimen) in second-line treatment for patients with metastatic colorectal cancer.Patients (...) . The secondary endpoints included the relative dose intensity, progression-free survival, overall survival and other adverse events.A total of 51 patients were enrolled. The incidence of grade ≥ 3 diarrhea was 15.7% (8/51). Other common grade ≥ 3 adverse events were neutropenia, anemia, thrombocytopenia and fatigue were 13.7% (7/51), 5.9% (3/51), 2.0% (1/51) and 5.9% (3/51), respectively. The relative dose intensities of irinotecan, bevacizumab, and S-1 were 80.0, 86.8, and 77.7%, respectively. The median

2018 Cancer chemotherapy and pharmacology

197. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. (Abstract)

day) was permitted if the drug was well tolerated. Patients, investigators, and those completing data analyses were masked to treatment allocation. Randomisation was stratified by age, response to second-line therapy, and prognostic factors. Co-primary endpoints were progression-free survival and overall survival; the primary endpoint was later changed to overall survival after the data cutoff for this analysis. Secondary endpoints were time from randomisation to second disease progression (...) Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. The efficacy and safety of lenalidomide as maintenance therapy after chemotherapy-based second-line therapy in patients with chronic lymphocytic leukaemia is unknown. Although kinase inhibitors can improve outcomes for some patients with relapsed and refractory disease, not all patients have access to these novel drugs. In this study

2018 The Lancet. Haematology Controlled trial quality: predicted high

198. A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Feasibility Study of Durvalumab (MEDI4736) Alone or in Combination With Oleclumab (MEDI9447) as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) Actual Study Start Date : February 20, 2019 Estimated Primary Completion Date : December 31, 2019 Estimated Study Completion Date : December 31, 2020 Resource links provided by the National Library of Medicine related topics: related topics: available (...) Receiving at least One Dose of Study Therapy Followed by Surgery without Dose-Limiting Toxicity (DLT) up to Twelve Weeks Post-Radical Cystectomy (RC) [ Time Frame: 2 years ] Secondary Outcome Measures : Number of Participants Receiving at least One Cycle of Study Therapy and Undergone RC Having

2018 Clinical Trials

199. Short Course Radiation Therapy in Palliative Treatment of Abdominal Cancer

: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: SHort Course Accelerated RadiatiON Therapy (SHARON) in Palliative Treatment of Abdominal Cancer: an Interventional, Randomized, Multicentric Study Actual Study Start Date : November 8, 2017 Estimated Primary Completion Date : November 8, 2022 Estimated Study Completion Date : November 8, 2023 Resource links provided by the National Library of Medicine related topics: Arms (...) : Efficacy of palliation using the short course scheme compared with the standard scheme [ Time Frame: 3 months ] Reduction of initial symptoms after radiotherapy, assessed with Likert scale (bleeding, nausea or vomiting, diarrhea, malnutrition, jaundice, weight loss, bowel obstruction are evaluated as none-mild-moderate-severe) Secondary Outcome Measures : acute toxicity in the two treatment groups [ Time Frame: 3 months ] incidence of treatment-related acute adverse events in the two arms of the study

2018 Clinical Trials

200. Second-line Therapy With Nal-IRI After Failure Gemcitabine/Nab-paclitaxel in Advanced Pancreatic Cancer

function Diarrhea Drug related criteria: Medication that is known to interfere with any of the agents applied in the trial. Known dihydropyrimidine dehydrogenase (DPD) deficiency History of hypersensitivity to any of the study drugs or any of the constituents of the products. Any other efficacious cancer treatment except protocol specified treatment at study start. Safety criteria: Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who (...) therapy Condition or disease Intervention/treatment Phase Locally Advanced Pancreatic Cancer Metastatic Pancreatic Cancer Drug: Irinotecan Liposomal Injection [Onivyde] Phase 3 Detailed Description: Research hypothesis: Patients profit from 2nd-line therapy with Nal-IRI if they also had a benefit from 1st-line treatment. Benefit from treatment (either 1st or 2nd-line) will be defined as a patient specific Time-To-Treatment Failure (TTF) which is in the upper third of the distribution of TTF values

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>